Pemafibrate prevents retinal pathological neovascularization by increasing FGF21 level in a murine oxygen-induced retinopathy model

Yohei Tomita, Nobuhiro Ozawa, Yukihiro Miwa, Ayako Ishida, Masayuki Ohta, Kazuo Tsubota, Toshihide Kurihara

Research output: Contribution to journalArticle

Abstract

Large-scale clinical trials, such as the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies, have shown that the administration of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, suppresses the progression of diabetic retinopathy. In this paper, we reveal a therapeutic effect of a selective PPARα modulator (SPPARMα), pemafibrate, against pathological angiogenesis in murine models of retinopathy. Oxygen-induced retinopathy (OIR) was induced in C57BL/6J mice by exposure to 85% oxygen from postnatal day eight (P8) for 72 h. Vehicle, pemafibrate or fenofibrate was administrated by oral gavage from P12 to P16 daily. Administration of pemafibrate, but not fenofibrate, significantly reduced pathological angiogenesis in OIR. After oral pemafibrate administration, expression levels of downstream PPARα targets such as acyl-CoA oxidase 1 (Acox1), fatty acid binding protein 4 (Fabp4), and fibroblast growth factor 21 (Fgf21) were significantly increased in the liver but not in the retina. A significant increase in plasma FGF21 and reduced retinal hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor A (Vegfa) were also observed after this treatment. In an in vitro HIF-luciferase assay, a long-acting FGF21 analogue, but not pemafibrate, suppressed HIF activity. These data indicate that SPPARMα pemafibrate administration may prevent retinal pathological neovascularization by upregulating FGF21 in the liver.

Original languageEnglish
Article number5878
JournalInternational journal of molecular sciences
Volume20
Issue number23
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Pathologic Neovascularization
Retinal Neovascularization
Fenofibrate
angiogenesis
PPAR alpha
Oxygen
oxygen
Medical problems
liver
Liver
Modulators
modulators
Acyl-CoA Oxidase
Hypoxia-Inducible Factor 1
Fatty Acid-Binding Proteins
Peroxisome Proliferator-Activated Receptors
retina
oxidase
hypoxia
fibroblasts

Keywords

  • Diabetes retinopathy
  • Fibroblast growth factor 21 (FGF21)
  • Hypoxia-inducible factor (HIF)
  • Selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα)
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Pemafibrate prevents retinal pathological neovascularization by increasing FGF21 level in a murine oxygen-induced retinopathy model. / Tomita, Yohei; Ozawa, Nobuhiro; Miwa, Yukihiro; Ishida, Ayako; Ohta, Masayuki; Tsubota, Kazuo; Kurihara, Toshihide.

In: International journal of molecular sciences, Vol. 20, No. 23, 5878, 01.12.2019.

Research output: Contribution to journalArticle

Tomita, Yohei ; Ozawa, Nobuhiro ; Miwa, Yukihiro ; Ishida, Ayako ; Ohta, Masayuki ; Tsubota, Kazuo ; Kurihara, Toshihide. / Pemafibrate prevents retinal pathological neovascularization by increasing FGF21 level in a murine oxygen-induced retinopathy model. In: International journal of molecular sciences. 2019 ; Vol. 20, No. 23.
@article{5b48318532094130b533980bc22036b1,
title = "Pemafibrate prevents retinal pathological neovascularization by increasing FGF21 level in a murine oxygen-induced retinopathy model",
abstract = "Large-scale clinical trials, such as the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies, have shown that the administration of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, suppresses the progression of diabetic retinopathy. In this paper, we reveal a therapeutic effect of a selective PPARα modulator (SPPARMα), pemafibrate, against pathological angiogenesis in murine models of retinopathy. Oxygen-induced retinopathy (OIR) was induced in C57BL/6J mice by exposure to 85{\%} oxygen from postnatal day eight (P8) for 72 h. Vehicle, pemafibrate or fenofibrate was administrated by oral gavage from P12 to P16 daily. Administration of pemafibrate, but not fenofibrate, significantly reduced pathological angiogenesis in OIR. After oral pemafibrate administration, expression levels of downstream PPARα targets such as acyl-CoA oxidase 1 (Acox1), fatty acid binding protein 4 (Fabp4), and fibroblast growth factor 21 (Fgf21) were significantly increased in the liver but not in the retina. A significant increase in plasma FGF21 and reduced retinal hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor A (Vegfa) were also observed after this treatment. In an in vitro HIF-luciferase assay, a long-acting FGF21 analogue, but not pemafibrate, suppressed HIF activity. These data indicate that SPPARMα pemafibrate administration may prevent retinal pathological neovascularization by upregulating FGF21 in the liver.",
keywords = "Diabetes retinopathy, Fibroblast growth factor 21 (FGF21), Hypoxia-inducible factor (HIF), Selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα), Vascular endothelial growth factor (VEGF)",
author = "Yohei Tomita and Nobuhiro Ozawa and Yukihiro Miwa and Ayako Ishida and Masayuki Ohta and Kazuo Tsubota and Toshihide Kurihara",
year = "2019",
month = "12",
day = "1",
doi = "10.3390/ijms20235878",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "23",

}

TY - JOUR

T1 - Pemafibrate prevents retinal pathological neovascularization by increasing FGF21 level in a murine oxygen-induced retinopathy model

AU - Tomita, Yohei

AU - Ozawa, Nobuhiro

AU - Miwa, Yukihiro

AU - Ishida, Ayako

AU - Ohta, Masayuki

AU - Tsubota, Kazuo

AU - Kurihara, Toshihide

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Large-scale clinical trials, such as the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies, have shown that the administration of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, suppresses the progression of diabetic retinopathy. In this paper, we reveal a therapeutic effect of a selective PPARα modulator (SPPARMα), pemafibrate, against pathological angiogenesis in murine models of retinopathy. Oxygen-induced retinopathy (OIR) was induced in C57BL/6J mice by exposure to 85% oxygen from postnatal day eight (P8) for 72 h. Vehicle, pemafibrate or fenofibrate was administrated by oral gavage from P12 to P16 daily. Administration of pemafibrate, but not fenofibrate, significantly reduced pathological angiogenesis in OIR. After oral pemafibrate administration, expression levels of downstream PPARα targets such as acyl-CoA oxidase 1 (Acox1), fatty acid binding protein 4 (Fabp4), and fibroblast growth factor 21 (Fgf21) were significantly increased in the liver but not in the retina. A significant increase in plasma FGF21 and reduced retinal hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor A (Vegfa) were also observed after this treatment. In an in vitro HIF-luciferase assay, a long-acting FGF21 analogue, but not pemafibrate, suppressed HIF activity. These data indicate that SPPARMα pemafibrate administration may prevent retinal pathological neovascularization by upregulating FGF21 in the liver.

AB - Large-scale clinical trials, such as the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies, have shown that the administration of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, suppresses the progression of diabetic retinopathy. In this paper, we reveal a therapeutic effect of a selective PPARα modulator (SPPARMα), pemafibrate, against pathological angiogenesis in murine models of retinopathy. Oxygen-induced retinopathy (OIR) was induced in C57BL/6J mice by exposure to 85% oxygen from postnatal day eight (P8) for 72 h. Vehicle, pemafibrate or fenofibrate was administrated by oral gavage from P12 to P16 daily. Administration of pemafibrate, but not fenofibrate, significantly reduced pathological angiogenesis in OIR. After oral pemafibrate administration, expression levels of downstream PPARα targets such as acyl-CoA oxidase 1 (Acox1), fatty acid binding protein 4 (Fabp4), and fibroblast growth factor 21 (Fgf21) were significantly increased in the liver but not in the retina. A significant increase in plasma FGF21 and reduced retinal hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor A (Vegfa) were also observed after this treatment. In an in vitro HIF-luciferase assay, a long-acting FGF21 analogue, but not pemafibrate, suppressed HIF activity. These data indicate that SPPARMα pemafibrate administration may prevent retinal pathological neovascularization by upregulating FGF21 in the liver.

KW - Diabetes retinopathy

KW - Fibroblast growth factor 21 (FGF21)

KW - Hypoxia-inducible factor (HIF)

KW - Selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα)

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=85075435868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075435868&partnerID=8YFLogxK

U2 - 10.3390/ijms20235878

DO - 10.3390/ijms20235878

M3 - Article

C2 - 31771164

AN - SCOPUS:85075435868

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 23

M1 - 5878

ER -